

Monthly DRUP Study Newsletter #81, 01 January 2023

The Drug Rediscovery Protocol (DRUP Trial):

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile



Study update

First of all, we want to wish you all a happy and healthy 2023! 2022 was a year with great achievements (see attached annual overview 2022) and we are hoping 2023 to be at least as brilliant as 2022.

2022 was rounded off with more than 1300 enrolled patients, which makes in average 200 patients per year for the 6,5 years the study has been open for inclusion. Currently we collaborate with more than 10 pharmaceutical companies and we have about 30 different treatment options.

We are pleased to announce that the drug selpercatinib from Lilly will be available in DRUP very soon. As soon as the medication becomes available we can start including patients for this drug. All patients who have an activating RET gene alteration (fusion or mutation) will be eligible for treatment with selpercatinib. Important to note is that only RNA-NGS is considered as an acceptable method to detect RET fusions. Most commonly observed RET-fusion partners are: NCOA4, CCDC6, KIF5B, ETV6, TRIM24, ERC1, GOLGA5, GPHN, PRKAR1A, RASAL2, CGNL1, SPECC1L, TAF3, TFG and TRIM33.

And there are more new drugs in the pipeline; niraparib and tepotinib will hopefully be available as treatment option within DRUP in the very near future. The contract negotiations are in progress.

Unfortunately, from now onwards are regorafenib and rucaparib both no longer treatment options within DRUP. Regorafenib inclusion was stopped because we have good alternatives and have not included patients in any of the cohorts for the last 2 years and rucaparib unfortunately was withdrawn by the manufacturer Clovis because they had to file for bankruptcy.

KWF implementation grant awarded for continuation DRUP

We are very happy to inform you that KWF has awarded our grant application for continuation of the DRUP infrastructure. Earlier this year we submitted this grant application to KWF to ensure continuity of DRUP in the coming years. Although we have included >1300 patients DRUP is not self-sustainable and, on top of the support by our pharma partners, heavily depends on Stelvio for Life and KWF. In the future we strive to further improve and professionalize the DRUP infrastructure. Moreover, we are establishing an international collaboration of DRUP-like studies to facilitate data sharing, to collect more data for rare combinations of tumor types and 'actionable' molecular variants, and to validate and implement therapies more easily.

We wish everyone who has contributed to the ongoing success of DRUP a very good 2023!,

Best regards,

Principal Investigators: Henk Verheul, Hans Gelderblom, Emile Voest

Study Coordinators: Laurien Zeverijn, Birgit Geurts, Ilse Spiekman, Karlijn Verkerk, Georgy Gomon

Clinical Project Manager: Lena Bilet

Table 1: List of pharmaceutical companies & study drugs

Confidential, list might be subjected to change

Currently available

<u>Amgen</u> Panitumumab	<u>Eisai</u> Lenvatinib	<u>MSD</u> Pembrolizumab	<u>Roche</u> Erlotinib Trastuzumab+ Pertuzumab
<u>BMS</u> Nivolumab Ipilimumab	<u>AstraZeneca</u> Olaparib Durvalumab	<u>Lilly</u> Abemaciclib Selpercatinib	Vemurafenib+ Cobimetinib Vismodegib Atezolizumab+ bevacizumab
<u>Novartis</u> Dabrafenib Nilotinib Trametinib Alpelisib	<u>Pfizer</u> Axitinib Crizotinib Sunitinib Talazoparib Dacomitinib Lorlatinib	<u>Janssen</u> Erdafitinib	Alectinib Entrectinib

Committed

<u>GSK</u> Niraparib	<u>Merck</u> Tepotinib
-------------------------	---------------------------

Calendar & publicity

--

Table 2: Submission and accrual overview stage 1,2 & 3 cohorts

Jan 1st, 2023

